<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332174</url>
  </required_header>
  <id_info>
    <org_study_id>TJXH-Rufi</org_study_id>
    <nct_id>NCT02332174</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects</brief_title>
  <official_title>Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the pharmacokinetic (PK) and safety profile of&#xD;
      single and multiple doses of rufinamide. The effects of food and sex on the PK properties of&#xD;
      rufinamide in these Chinese volunteers were also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single- and multiple-dose, randomized, open-label study was conducted in healthy Chinese&#xD;
      subjects. In the single-dose study, volunteers were randomly assigned to 4 dose groups and&#xD;
      received a single dose of 200, 400, 800, 1200 mg rufinamide tablets under fasted condition.&#xD;
      An additional food effect study was performed in the 200-mg dose group by assessing changes&#xD;
      in PK parameters after high-fat diet. In the multiple-dose study, 10 subjects were&#xD;
      administered 200-mg rufinamide formulation twice daily for 6 consecutive days. LC-MS/MS&#xD;
      method was applied to determine plasma concentration of rufinamide. Tolerability was assessed&#xD;
      based on investigator inquiries, spontaneous reports, and clinical evaluations such as&#xD;
      standard laboratory tests, vital signs, physical examinations and 12-lead&#xD;
      electrocardiography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>three days</time_frame>
    <description>the area under the concentration-time curve</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>200-mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten healthy subjects were administered a single oral dose of 200 mg rufinamide tablets in fasted and fed state at day 1 and then received repeated oral doses of rufinamide (200 mg) once daily for 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400-mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten healthy subjects were administered a single oral dose of 400 mg rufinamide tablets in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800-mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten healthy subjects were administered a single oral dose of 800 mg rufinamide tablets in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1200-mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten healthy subjects were administered a single oral dose of 1200 mg rufinamide tablets in fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rufinamide</intervention_name>
    <description>comparison of different doses, sex and medication conditions</description>
    <arm_group_label>1200-mg group</arm_group_label>
    <arm_group_label>200-mg group</arm_group_label>
    <arm_group_label>400-mg group</arm_group_label>
    <arm_group_label>800-mg group</arm_group_label>
    <other_name>106308-44-5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  body mass index between19 and 24 kg/m2&#xD;
&#xD;
          -  negative for HIV and hepatitis B&#xD;
&#xD;
          -  had no clinicallyimportant findings on health tests&#xD;
&#xD;
          -  thorax radiography and ECG with no abnormalities&#xD;
&#xD;
          -  normal blood pressure values&#xD;
&#xD;
          -  heart rate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any drug treatment within 2 weeks before starting the study&#xD;
&#xD;
          -  participation in another clinical study within the previous 3 months&#xD;
&#xD;
          -  alcoholism and smoking&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breast-feeding&#xD;
&#xD;
          -  hypocalcemia&#xD;
&#xD;
          -  blood donation or participation in other clinical trials within 3 months before&#xD;
             enrollment in the study&#xD;
&#xD;
          -  sitting blood pressure &lt;80/50 mm Hg or &gt;140/100 mm Hg&#xD;
&#xD;
          -  A ventricular rate &lt;60 beats/min or &gt;100 beats/min at rest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiyong Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Medical College, Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 3, 2015</study_first_submitted>
  <study_first_submitted_qc>January 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>January 3, 2015</last_update_submitted>
  <last_update_submitted_qc>January 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Weiyong Li</investigator_full_name>
    <investigator_title>Institute of Clinical Pharmacy</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>food effect</keyword>
  <keyword>sex effect</keyword>
  <keyword>tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rufinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

